# Laurence Albigès

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/laurence-albiges/

## Facts

| Field | Value |
| --- | --- |
| Citations | 37,942 |
| Field | Renal cell carcinoma treatment |
| h-index | 83 |
| i10-index | 320 |
| Last Known Institution | Inserm |
| OpenAlex ID | https://openalex.org/A5074162105 |
| ORCID iD | https://orcid.org/0000-0002-5734-3480 |
| Works | 1,028 |

## Researcher papers

- [Gut microbiome influences efficacy of PD-1–based immunotherapy against epithelial tumors](https://scholariq.org/papers/gut-microbiome-influences-efficacy-of-pd-1-based-immunotherapy-against/)
- [Avelumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma](https://scholariq.org/papers/avelumab-plus-axitinib-versus-sunitinib-for-advanced-renal-cell-carcinoma/)
- [Sunitinib Alone or after Nephrectomy in Metastatic Renal-Cell Carcinoma](https://scholariq.org/papers/sunitinib-alone-or-after-nephrectomy-in-metastatic-renal-cell-carcinoma/)
- [Renal cell carcinoma: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up](https://scholariq.org/papers/renal-cell-carcinoma-esmo-clinical-practice-guideline-for-diagnosis-treatment/)
- [Managing cancer patients during the COVID-19 pandemic: an ESMO multidisciplinary expert consensus](https://scholariq.org/papers/managing-cancer-patients-during-the-covid-19-pandemic-an-esmo-multidisciplinary/)
- [Atezolizumab plus cabozantinib versus cabozantinib monotherapy for patients with renal cell carcinoma after progression with previous immune checkpoint inhibitor treatment (CONTACT-03): a multicentre, randomised, open-label, phase 3 trial](https://scholariq.org/papers/atezolizumab-plus-cabozantinib-versus-cabozantinib-monotherapy-for-patients-with/)
- [Adjuvant nivolumab plus ipilimumab versus placebo for localised renal cell carcinoma after nephrectomy (CheckMate 914): a double-blind, randomised, phase 3 trial](https://scholariq.org/papers/adjuvant-nivolumab-plus-ipilimumab-versus-placebo-for-localised-renal-cell/)

## Researcher topics

- [Renal cell carcinoma treatment](https://scholariq.org/topics/renal-cell-carcinoma-treatment/)
- [Cancer Genomics and Diagnostics](https://scholariq.org/topics/cancer-genomics-and-diagnostics/)
- [Cancer Immunotherapy and Biomarkers](https://scholariq.org/topics/cancer-immunotherapy-and-biomarkers/)
- [Prostate Cancer Treatment and Research](https://scholariq.org/topics/prostate-cancer-treatment-and-research/)
- [Renal and related cancers](https://scholariq.org/topics/renal-and-related-cancers/)

## Researcher university

- [Inserm](https://scholariq.org/institutions/inserm/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.